Menu Breaking news sponsored byAs one of the 785 companies in the GICS Health Care sector Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a member of the 349 company Biotechnology GICS industry group within this sector. VRTX's market value is $37.9 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for VRTX puts it 81 among the 349 companies in this industry group, putting in the top quartile; in the top half of the sector with a ranking of 222 among the 785 companies in the sector, and number 1,463 in the nearly 5,000 company Portfolio Grader universe.VRTX has a current recommendation of Buy using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator.  VRTX has maintained this ranking for 4 months.Portfolio Grader currently ranks the Health Care sector number 10 among the 12 sectors in its universe putting it in the bottom quartile of all the GICS sectors. The Biotechnology industry group is ranked 50 among the 69 industry groups within the GICS sectors, placing it below-average in terms of the Navellier scoring system.Vertex Pharmaceuticals has achieved above-average scores in 4 of the 8 fundamental areas appraised by Portfolio Grader and average or below-average grades in 4 of the areas used in the ranking of company stocks.The company's operational scores provide mixed results with a ranking for sales growth that is well above the industry average but rankings for operating margin and earnings growth are below average.  Scores for visibility of earnings are mixed, with a ranking for earnings revisions and earnings surprises that are significantly better than average, while the score for earnings momentum is much worse than average. VRTX's metric for return on equity is discernibly better than its industry group average but its ranking for cash flow is below-average.  Vertex Pharmaceuticals' fundamental scores give VRTX a place in the top quartile of the industry group. Portfolio Grader quantitatively measures VRTX's shares using the Navellier Proprietary Quantitative Score. This metric looks at VRTX's shares from the perspective of risk/reward. This unique scoring methodology takes into account the relative value of VRTX's shares based on the current price of the shares relative to its peers, the market and risk associated with its industry and sector groups. Using this risk/reward calculation, the company currently scores above-average in its industry group compared to its peers.Louis Navellier's proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results, with A being 'strong buy' and F being 'strong sell'.  Explore the tool here.Commentary provided by UpTick Data Technologies.Article printed from InvestorPlace Media, https://investorplace.com/2017/11/vertex-pharmaceuticals-vrtx-a-buy-on-strong-sales-growth/.©2017 InvestorPlace Media, LLC

								About Us							
							  ·  													
								Press Center							
							  ·  													
								Resources							
							  ·  													
								Advisory Services							
							  ·  													
								Free Newsletters							
							  ·  													
								Free Reports							
							  ·  													
								Contact Us							
							  ·  													
								Advertise With Us							
							  ·  													
								Employment							
							  ·  													
								Privacy							
							  ·  													
								Terms and Conditions							
							  ·  													
								Disclosures and Disclaimers							
							  ·  													
								Media Sites							


								RSS							
							  ·  													
								Sitemap							

More On InvestorPlace:
Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.Copyright © 2017 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.